Discover and read the best of Twitter Threads about #Mucosal
Most recents (7)
GREAT NEWS / BREAKING
First phase III #Covid19 #intranasal #vaccine data released.
IT LOOKS VERY GOOD!
@BharatBiotech s intranasal #iNCOVACC has a 45% higher antibody titer than their intramuscular #Covaxin.
And it shows a satisfactory immune response against Omicron BA.5.
First phase III #Covid19 #intranasal #vaccine data released.
IT LOOKS VERY GOOD!
@BharatBiotech s intranasal #iNCOVACC has a 45% higher antibody titer than their intramuscular #Covaxin.
And it shows a satisfactory immune response against Omicron BA.5.
2
Source: @BharatBiotech just published the pack insert for the intranasal vaccine:
bharatbiotech.com/images/incovac… (p. 7)
This is from their updated their website for #iNCOVACC:
bharatbiotech.com/intranasal-vac…
H/T to @Pdr_US for alerting me to that change and the new documents!
Source: @BharatBiotech just published the pack insert for the intranasal vaccine:
bharatbiotech.com/images/incovac… (p. 7)
This is from their updated their website for #iNCOVACC:
bharatbiotech.com/intranasal-vac…
H/T to @Pdr_US for alerting me to that change and the new documents!
3
That @BharatBiotech published a vaccine pack insert and a summary of product characteristics (SMPC) shows to me that they are very far along in the release process.
The primary course vaccine has been authorized in India, we are still waiting on authorization of booster use.
That @BharatBiotech published a vaccine pack insert and a summary of product characteristics (SMPC) shows to me that they are very far along in the release process.
The primary course vaccine has been authorized in India, we are still waiting on authorization of booster use.
I'm excited to share with you our recent @biorxivpreprint where we demonstrate that @vaxart mucosal Ad5 #SARSCoV2 vaccines not only protected against disease but also reduced transmission after post-#vaccination #SARSCoV2 infection in a hamster model. biorxiv.org/content/10.110… A🧵/
If you follow me, you are well aware of my obsession w/ #mucosalimmunity.😂Protection generated at mucosal surfaces is at the crux of one of the biggest questions we need to answer during this unique phase of the #pandemic - How do we decrease #SARSCoV2 #transmission to others.
Considering most of the world is unimmunized (including most kids <12), the possibility that a vaccinated individual with a post-vaccination infection (aka #breakthrough) can spread #SARSCoV2 is a public health risk. We need #transmissionblocking strategies.
After 6 months of #lockdown and #lab shutdown I spent a full day 9 am-8 pm in lab doing experiments! New #grad students in #lifesciences: There is always light 💡 and #fluorescent images at the end of the tunnel! Filing a #patent on my #invention from #phd work soon @OrganOnAChip
This is an Organ on a Chip platform that enables mimicking #tissues and #organs in a high throughput manner! The main focus will be towards developing #mucosal organs with tissue resident #immune cells and lining #epithelial cells for #testing #COVID19 treatments #covidvaccines
I recently gave a talk at #oooc2020 organized by @GVNlab at @Columbia. In the talk I demonstrated the #ease of fabrication, #functionality, and #modularity of this platform.
We’re open to #collaborate with interested #researchers! Interested to learn more:
We’re open to #collaborate with interested #researchers! Interested to learn more:
Our research team @CUHKMedicine analysed >300 specimens from 14 #HongKong patients confirmed with #COVID19 and discovered that the virus was detectable in the #stool samples of all patients, regardless of the degree of illness.
3 out of 14 patients still had viruses in their #stool samples even though the virus was no longer found in #sputum, nasopharyngeal and deep throat saliva samples.
Our study suggests that virus shedding in stool may have public health implications. First, it may serve as an alternative #screening tool in people without #respiratory symptoms.
#WSV2019 #Welcome_reception
Panel #discussion of the #prospective #plans of @WSVirology
#USA @uppsalauni @karolinskainst @ESCMID @ESCVirology @swedishvirology @SLU_Virology @RedMexVirologia @sareengalbraith @rosamdelangel @foodsafetynews @VirolColombia @AusVirologySoc
Panel #discussion of the #prospective #plans of @WSVirology
#USA @uppsalauni @karolinskainst @ESCMID @ESCVirology @swedishvirology @SLU_Virology @RedMexVirologia @sareengalbraith @rosamdelangel @foodsafetynews @VirolColombia @AusVirologySoc
@uppsalauni @karolinskainst @ESCMID @ESCVirology @swedishvirology @SLU_Virology @RedMexVirologia @sareengalbraith @rosamdelangel @foodsafetynews @VirolColombia @AusVirologySoc #WSV2019 | #Janusz_Paweska | Wonderful Presentation of #South_African #mobile_laboratory_response to #Ebola outbreak in #West_Africa in the first meeting of WSV @WSVirology, #Stockholm 2019
ws-virology.org
@VirolColombia @RedMexVirologia @AusVirologySoc @edrybicki
ws-virology.org
@VirolColombia @RedMexVirologia @AusVirologySoc @edrybicki
@uppsalauni @karolinskainst @ESCMID @ESCVirology @swedishvirology @SLU_Virology @RedMexVirologia @sareengalbraith @rosamdelangel @foodsafetynews @VirolColombia @AusVirologySoc @edrybicki #WSV2019 | Prof. #Ziad_Memish | #MERS_CoV an emerging #virus from the #ArabianPeninsula in the first meeting of WSV@WSVirology, #Stockholm 2019
ws-virology.org
@VirolColombia @RedMexVirologia @AusVirologySoc #coronavirus #SaudiNationalDay #SaudiArabia @Alfaisaluniv
ws-virology.org
@VirolColombia @RedMexVirologia @AusVirologySoc #coronavirus #SaudiNationalDay #SaudiArabia @Alfaisaluniv
#melanoma #medtwitter, our latest is out in @CancerRes_12: please test for ERBB2 amplifications in your "triple WT" #mucosal #acral #melanoma populations post-PD1 (6-7%). We describe a durable CR with TDM-1. clincancerres.aacrjournals.org/content/early/…
Proud to have worked with a talented medical student through this process. Senior author feels >> first author feels!
Important to note that Her2/ERBB2 amplifications ≠ mutations. The latter were almost always co-altered with another classic MAPK driver. Maybe they are more resistant to targeted monotherapy? CC: @DHymanMD
1/ Some #melanoma posters and talks I'm excited to learn more about at @ASCO 2018:
#uveal 1 year OS 74% in @Immunocore Ph1b expansion of IMCgp100 (disclosure: I'm on ad board) meetinglibrary.asco.org/record/162309/…
#uveal 1 year OS 74% in @Immunocore Ph1b expansion of IMCgp100 (disclosure: I'm on ad board) meetinglibrary.asco.org/record/162309/…
2/ #uveal modest activity with BET inhibition as monotherapy
meetinglibrary.asco.org/record/158612/…
and
meetinglibrary.asco.org/record/160188/…
meetinglibrary.asco.org/record/158612/…
and
meetinglibrary.asco.org/record/160188/…
3/ #mucosal important Phase 3 of adjuvant platinum-based chemo vs interferon:
meetinglibrary.asco.org/record/162094/…
Cisplatin + temozolomide mPFS 15 mo, mOS 40 mo - not too much worse than the Phase 2 data. Should chemo be standard adjuvant therapy?
meetinglibrary.asco.org/record/162094/…
Cisplatin + temozolomide mPFS 15 mo, mOS 40 mo - not too much worse than the Phase 2 data. Should chemo be standard adjuvant therapy?
